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CLINICAL INQUIRIES
What is the initial work-up 
in the diagnosis of hypertension?
■ Evidence summary
There are currently no large outcome 
studies evaluating the initial work-up of
hypertension; however, 4 international
expert panels have published recommen-
dations.2–5 These panels advise 3 initial
objectives: 1) assess lifestyle and identify
other cardiovascular risk factors or 
concomitant disorders that may affect
prognosis and guide treatment; 2) search
for treatable causes of high blood pressure;
and 3) assess for the presence of target
organ damage that would change the 
management of the patient (such as chron-
ic kidney disease or heart disease). 
In addition to a thorough history and
physical, the following studies are recom-
mended for patients with newly diagnosed
hypertension:
Serum potassium and creatinine. All 
4 panels recommend measuring serum
potassium and creatinine in order to: 1)
monitor the effects of diuretics and
angiotensin-converting enzyme (ACE)
inhibitors used in hypertension therapy, 2)
screen for unexplained hypokalemia that
may indicate a low-renin form of hyper-
tension, 3) calculate baseline creatinine
clearance, and 4) screen for chronic kidney
disease. 
Fasting blood glucose. All 4 panels 
recommend measuring a fasting glucose
level to screen for diabetes. An abnormal
glucose level may also reveal glucose intol-
erance, one of the diagnostic criteria of
metabolic syndrome. Up to 60% of patients
with diabetes also have hypertension.6
Fasting lipid panel. All 4 expert panels
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Patients with a new diagnosis of hypertension
should be evaluated with a history and physical
exam and the following initial studies: serum
potassium and creatinine, fasting serum glucose
and lipid panel, hematocrit, urinalysis, and 
electrocardiogram (strength of recommendation
[SOR]: C, based on a consensus of expert 
opinion). Consensus is lacking for measuring
serum sodium, calcium, and uric acid. 
Testing for microalbuminuria is optional 
in the work-up for a patient without diabetes
(SOR: C, expert consensus). Some expert 
panels list limited echocardiography as 
another option.
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Not all recommendations for working-up 
hypertensive patients are cost-effective
There is obvious enthusiasm among the expert
panels for a detailed workup of patients with
hypertension. But are the recommendations 
cost-effective? Annual urine dipstick testing
beginning at age 30 for hypertensive patients is
highly cost-effective. Identification of proteinuria
and treatment with an ACE inhibitor or
angiotensin receptor blocker prevents the 
progression of renal disease at a quality-adjusted
life-year cost of $15,484 to $26,320, depending on
the age group.1 Unfortunately, evaluation for 
secondary causes of hypertension, screening for
LVH, and ruling out comorbidities have not been
explicitly evaluated for cost-effectiveness.
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recommend screening for dyslipidemia with
a fasting lipid panel to assess cardiovascular
risk. A cohort study evaluating 356,222
men aged 35 to 57 years found a continu-
ous, positive, graded correlation between
plasma cholesterol levels and coronary risk.7
Hematocrit. All 4 panels recommend a
hematocrit to screen for anemia, which
may be due to chronic kidney disease.
Urinalysis. All 4 panels recommend a
urinalysis to screen for renal disease.
Electrocardiogram (ECG). All 4 panels
recommend an ECG to screen for findings
associated with hypertension, including
left ventricular hypertrophy (LVH),
myocardial infarction, and rhythm abnor-
malities. A cohort study followed 2363
patients for 14 years who had untreated
hypertension and were without pre-exist-
ing cardiovascular disease. After control-
ling for age, sex, diabetes, and mean blood
pressure, LVH by ECG conferred a signifi-
cant increased risk for cerebrovascular
events (relative risk=1.79; 95% confidence
interval [CI], 1.17–2.76).8 However, in a
cohort of 4684 subjects from the
Framingham Heart Study, ECG had a sen-
sitivity of only 6.9% for the detection of
LVH (specificity 98.8%; positive likeli-
hood ratio=5.3; negative likelihood
ratio=0.94).8
Echocardiography. Two panels3,4 and
an online text10 recommend echocardiog-
raphy, preferably limited echo, as an
optional study. A systematic review of
studies comparing the sensitivities and
specificities of ECG and echo found that
each was highly specific for the detection
of LVH (77%–97%), but the sensitivity of
echocardiography (88%–93%) exceeded
that of ECG (21%–54%). However, LVH
detected by ECG is a better predictor of
cardiovascular complications.11 Because
echocardiography may help assess disease
duration and guide management, both
panels recommend it for patients with
severe or refractory hypertension but 
without other target organ damage. 
Microalbuminuria. All panels listed
microalbuminuria testing as an optional
study for patients without diabetes because
of its association with an increased inci-
dence of cerebrovascular disease.12 It is
unclear whether microalbuminuria results
from the increased intraglomerular pres-
sure in hypertension or if it represents
glomerular damage.13
Sodium, calcium, uric acid. There is no
consensus on the routine inclusion of sever-
al studies: serum sodium (recommended by
2 panels and an online text4,5,10), serum cal-
cium (recommended by 1 panel and the
text2,10), and uric acid (1 panel3 recom-
mends it while the text10 lists it as optional). 
Recommendations from others
Recommendations from major organiza-
tions are included in Evidence Summary,
above.
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What are 
Clinical Inquiries?
Clinical Inquiries answer recent questions from the 
practices of family physicians.  Practicing family physicians
choose the most relevant questions submitted through a
web-based voting system operated by the Family Physicians
Inquiries Network (FPIN; online at www.fpin.org). 
FPIN is national, not-for-profit consortium of family 
medicine departments, community residency programs, aca-
demic health sciences libraries, primary care practice-based
research networks, and other specialists. Once questions are
selected, FPIN editors then organize teams of clinicians and
librarians to answer them based on systematic review of the
world literature. Answers are developed through an explicit,
systematic method:
❚ FPIN librarians and editors identify questions recently
answered in best evidence sources (e.g. Cochrane Reviews,
Clinical Evidence, the US Preventive Services Task Force,
Evidence Based Guidelines, a published systematic
review).
❚ FPIN librarians then conduct systematic and 
standardized literature searches of best evidence sources,
Medline, and other databases in collaboration with an FPIN
clinician or clinicians. If a best evidence source has been
identified, the search begins from the date of the search
conducted for that source. Otherwise, the searches are 
comprehensive. 
❚ FPIN clinician authors then choose the highest quality 
original research sources, and critically appraise the
research and integrate the findings in the Evidence Based
Answer and Evidence Summary section of Clinical
Inquiries. Authoritative sources are also quoted in the
“Recommendations from Others” section of the Clinical
Inquiry.
❚ Each Clinical Inquiry is reviewed by 4 or more peers 
or editors before publication in JFP.
❚ FPIN medical librarians are accountable for the thoroughness
of the literature search, for recording the databases
searched, search hedges used and the search terms.  
The details of each search is available to any interested
reader (contact managingeditor@fpin.org).
❚ Finally, a practicing family physician or other clinician
writes an accompanying commentary to provide a clinical
perspective.
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